Assessment of T helper 17-associated cytokines in thromboangiitis obliterans
Received 2 June 2019
Accepted for publication 25 July 2019
Published 5 September 2019 Volume 2019:12 Pages 251—258
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Nicola Ludin
Peer reviewer comments 3
Editor who approved publication: Dr Ning Quan
Shayan Keramat,1 Mohammad Hadi Sadeghian,1,2 Mohammad Reza Keramati,1,2 Bahare Fazeli3,4
1Hematology Department, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; 2Pathology Department, Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 3Immunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 4Department of Angiology, L.Sacco Hospital, Vascular Independent Research and Education, European Organization, Milan, Italy
Correspondence: Bahare Fazeli
Immunology Department, Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine, Mashhad University of Medical Sciences, Pardis Campus, Azadi Sqr, Mashhad, Iran
Tel +98 513 800 2379
Fax +98 513 841 4499
Background: The management of thromboangiitis obliterans (TAO) remains a medical challenge because of its unknown etiology. It is also not known whether it is a systemic or localized disease or a type of autoimmune vasculitis.
Methods: In this study, we evaluated the serum level of IL-17 and IL-23 which increase in both systemic inflammation and autoimmunity, in 60 TAO patients and 30 age- and smoking habit-matched controls. Also, IL-22, which has reported high level during infection but not in autoimmunity, was evaluated.
Results: The serum levels of IL-17, IL-22 and IL-23 were significantly higher in the TAO patients in comparison with the controls (P<0.001). Notably, the serum levels of IL-17, IL-22 and IL-23 were highest in the patients with the chief complaint of chronic ulcer and lowest in the patients with gangrene (P<0.05). Also, the serum level of IL-22 was significantly higher in the anemic patients in comparison with the non-anemic patients (P=0.03).
Conclusion: Owing to our findings, TAO appears more likely to be a systemic disorder rather than a localized vasculopathy. Therefore, treatment protocols based on systemic treatment of TAO patients may be more helpful than localized treatment, such as bypass surgery and endovascular procedures. Also, according to our findings regarding the high level of IL-22, the trigger of TAO development may be an infectious pathogen. However, additional research is highly recommended to investigate whether TAO is an infectious disease or an infectious-induced autoimmunity.
Keywords: thromboangiitis obliterans, Buerger’s disease, autoimmunity, interleukin-17, interleukin-22, interleukin-23
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]